Discrepancy in MALDI-TOF MS identification of uncommon Gram-negative bacteria from lower respiratory secretions in patients with cystic fibrosis by Abdulwahab, Atqah et al.
© 2015 AbdulWahab et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)  
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on 
how to request permission may be found at: http://www.dovepress.com/permissions.php
Infection and Drug Resistance 2015:8 83–88
Infection and Drug Resistance Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
83
O R I g I n a l  R e s e a R c h
open access to scientific and medical research
Open access Full Text article
http://dx.doi.org/10.2147/IDR.S80341
Discrepancy in MALDI-TOF MS identification  
of uncommon gram-negative bacteria from  
lower respiratory secretions in patients  
with cystic fibrosis
atqah abdulWahab1,2
saad J Taj-aldeen3
emad Bashir Ibrahim3
eman Talaq4
Marawan abu-Madi4
Rashmi Fotedar5
1Department of Pediatrics, hamad 
Medical corporation, Doha, Qatar; 
2Department of Pediatrics, Weill 
cornell Medical college, Doha, 
Qatar; 3Microbiology Division, 
Department of laboratory 
Medicine and Pathology, hamad 
Medical corporation, Doha, Qatar; 
4Department of health sciences, 
college of arts and sciences, 
Qatar University, Doha, Qatar; 
5Biotechnology center, Ministry of 
environment, Doha, Qatar
correspondence: atqah abdulWahab 
Department of Pediatrics, hamad  
Medical corporation, PO Box 3050,  
Doha, Qatar 
Mobile +974 55 544 911 
Tel +974 44 392 834 
Fax +974 44 439 571 
email atqah2015@gmail.com
Introduction: Early identification of microbial organisms from respiratory secretions of 
patients with cystic fibrosis (CF) is important to guide therapeutic decisions. The objective 
was to compare the accuracy of matrix-assisted laser desorption/ionization-time of flight mass 
spectrometry (MALDI-TOF MS) relative to the conventional phenotypic method in identify-
ing common bacterial isolates, including nonfermenting Gram-negative bacteria, in a cohort 
of patients with CF.
Methods: A total of 123 isolates from 50 patients with CF representing 14 bacterial species 
from respiratory specimens were identified using MALDI-TOF MS in parallel with conven-
tional phenotypic methods. Discrepancies were confirmed by 16S ribosomal RNA (rRNA) gene 
sequencing in five Gram-negative isolates.
Results: The MALDI-TOF MS managed to identify 122/123 (99.2%) bacterial isolates to the 
genus level and 118/123 (95.9%) were identified to the species level. The MALDI-TOF MS 
results were 100% consistent to the species level with conventional phenotypic identification 
for isolates of Staphylococcus aureus, Pseudomonas aeruginosa, Haemophilus influenzae, 
Streptococcus pyogenes, Achromobacter xylosoxidans, Stenotrophomonas maltophilia, and other 
uncommon organisms such as Chryseobacterium gleum and Enterobacter cloacae. The 5/123 
(4.6%) isolates misidentified were all Gram-negative bacteria. The isolation of E. cloacae and 
Haemophilus paraphrohaemolyticus may extend the potentially pathogenic list of organisms 
isolated from patients with CF.
Conclusion: Although the technique provides an early identification and antimicrobial therapy 
approach in patients with CF, limitation in the diagnosis of uncommon Gram-negative bacteria 
may exist.
Keywords: cystic fibrosis, MALDI-TOF MS, bacteria, respiratory secretions, molecular 
identification
Introduction
Cystic fibrosis (CF) is the most common life-threatening recessive genetic disease 
among Caucasian races, with a frequency of about 1 in 2,500 live births.1 The underly-
ing basic defect in CF, the restriction of infection to the lung, and the chronic nature 
of infection characterize the vicious cycle of inflammation and respiratory infections. 
Patients with CF acquire a unique set of bacterial pathogens that are frequently isolated 
from the respiratory tract in an age-dependent sequence. Staphylococcus aureus is a 
frequent isolate and may be cultured early in infancy, Haemophilus influenzae is asso-
ciated with childhood and has been reported to be the most common CF pathogen at 
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the age of 1 year, and Pseudomonas aeruginosa is the most 
common pathogen in CF and the prevalence increases with 
age.2 With the improved survival, new emergent pathogens 
in the CF lung, such as other nonfermenting Gram-negative 
bacilli of undetermined clinical significance that can be 
isolated include Achromobacter xylosoxidans, Stenotroph-
omonas maltophilia, or species belonging to the Burkhold-
eria cepacia complex.3 Other uncommon bacterial species, 
such as Ralstonia mannitolilytica,4 Pandoraea apista,5 and 
Inquilinus limosus,6 have also been isolated from patients 
with CF. Bacteria isolated from patients with CF do not have 
the same virulence, and different bacterial species display 
distinct degrees of pathogenicity, thus requiring different 
clinical management approaches.7 Correct identification of 
these bacteria by conventional microbiology methods is often 
limited due to phenotypic misidentification.8
The development of 16S ribosomal RNA (rRNA) gene 
sequencing has succeeded in providing reliable results. 
However, it is still more expensive than most traditional 
identification methods and, therefore, its application is limited 
to large research and reference laboratories.9  Moreover, the 
emergence of new bacterial species in respiratory secretions 
of patients with CF requires rapid identification tools to start 
early antibacterial therapy. Matrix-assisted laser desorption/
ionization-time of flight mass spectrometry (MALDI-TOF 
MS) has been recently introduced in clinical microbiology 
laboratories as a newly emerging technology applied to the 
problem of bacterial species identification.10 Several studies 
have reported the use of MALDI-TOF MS for identification 
of bacteria, including nonfermenting Gram-negative bacteria 
(NFGNB).11,12 In addition, MALDI-TOF MS is a useful tool 
for the characterization of microorganisms that are difficult 
to identify using routine methods.
MALDI-TOF MS has proven to be cost effective and 
accurate for the identification of microorganisms, obviat-
ing the need for routine biochemical methods.13 Thus, in 
the present work, we used MALDI-TOF MS technology to 
identify common bacterial pathogens, including NFGNB, 
from patients with CF, to compare the outcome with pheno-
typic identification and confirm its discriminatory power for 
discrepant organisms with that of 16S rRNA gene sequence 
analysis.
Materials and methods
Patients and specimen collection
Fifty patients with CF were enrolled between July 1, 2013 and 
December 31, 2013. Sputum samples or deep-oropharyngeal 
swabs were prospectively collected from both pediatric 
and adult patients with CF at regular clinical examinations 
(patients were reviewed at 3-month intervals) as well as dur-
ing admission for acute exacerbation. The research and ethics 
committee of Hamad Medical Corporation (reference number 
12177/12) granted approval to conduct this study.
Routine identification
The organisms were cultivated on a variety of different 
media (Remel, Lenexa, KS, USA), including trypticase soy 
agar with 5% sheep blood, chocolate agar, MacConkey agar, 
mannitol salt agar, and B. cepacia-selective agar. Plates were 
incubated in ambient air or 5% CO
2
 at 35°C for 48 hours. 
After Gram staining, bacteria were further identified using 
catalase and oxidase tests. A small inoculum from a single 
colony of each isolate was used to prepare the inocula for bio-
chemical identification by Vitek II Compact® (BioMérieux, 
Marcy l’Etoile, France), and Phoenix™ (BD Diagnostics, 
Sparks Glencoe, MD, USA) as recommended by the manu-
facturer. In parallel, one single colony was directly deposited 
on a MALDI-TOF MS target plate (Bruker Daltonik GmbH, 
Bremen, Germany).
MalDI-TOF Ms measurement
MALDI-TOF MS measurements were performed with a 
60-Hz nitrogen laser and the spectra were analyzed over a 
mass range of 2–20 kDa. The strains from both reference and 
clinical sets were measured and identified by MALDI Biotyper 
RTC software 3.0 (Bruker Daltonik GmbH). Each series of 
measurements was preceded by calibration with a bacterial 
test standard (Bruker Daltonik GmbH). All specimens were 
processed as per manufacturer’s guidelines. Each sample 
was tested in duplicate to ensure reproducibility of spectra. 
Identification scores were interpreted according to the manu-
facturer’s recommended criteria: a score of .2.0 indicated 
species-level identification, a score of 1.70–1.999 indicated 
identification at the genus level, and a score of ,1.70 was 
interpreted as “not reliable identification.” The identification 
of the tested strain corresponds to the species of the reference 
strain with the best match in the database. When MALDI-TOF 
MS and phenotypic identifications agreed, no further analy-
ses were performed. Discrepancies at genus or species level 
were resolved with a molecular technique based on sequence 
analysis of 16S rRNA, which is considered the “gold standard” 
identification method.9
16s rRna gene sequencing
Further genomic studies were conducted to identify the 
five discrepant isolates using sequencing studies. Briefly, 
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DNA from pure cultures was obtained using Prepman DNA 
extraction kits with the MicroSEQ® ID software (Applied 
Biosystems, Foster City, CA, USA), and DNA estimation 
was done using the nanodrop method (NanoDrop ND 1000, 
Thermo Scientific, Waltham, MA, USA). For molecular 
identification of bacterial isolates, universal primers B27F and 
16R1492 and B27F and 1522 R based on the 16S rRNA gene 
were used in a polymerase chain reaction (PCR) to amplify 
the nearly complete 1,500-bp sequence. The PCR product was 
purified using Exo SAP-IT (Affymetrix, Inc., Santa Clara, CA, 
USA) and sequenced in both forward and reverse directions 
in duplicate using an ABI PRISM model 3130 automatic 
DNA sequencer and Big Dye Terminator cycle sequencing 
kit (Applied Biosystems). The 16S rRNA gene sequence was 
subjected to BLAST sequence similarity search.
Results
The 50 patients enrolled in this study comprised 29 males 
and 21 females; their mean age was 14.2±9.9 years. Thirty-
one patients with CF were ,18 years of age and 19 patients 
with CF were of $18 years of age. A total of 123 isolates 
from 83 samples representing 14 bacterial species were 
identified.
Conventional phenotypic and MALDI-TOF MS iden-
tification results are shown in Figure 1. The performance 
of the MALDI-TOF MS system was, compared to rou-
tine conventional methodology for commonly isolated 
bacteria, faster requiring shorter time for identification. 
The MALDI-TOF MS correctly identif ied 122/123 
(99.2%) [log (score): ,2 and $1.7] of the studied isolates 
at the genus level when compared to routine biochemical 
phenotypic tests, but the accuracy decreased to 95.9% 
(118/123) [log (score): $2] at the species level. Both meth-
ods showed full concordance for 50 isolates of S. aureus, 
39 P. aeruginosa, 16 H. influenzae, three Streptococcus 
pyogenes ,  three A. xylosoxidans ,  two Moraxella 
catarrhalis, and one isolate each of Haemophilus parain-
fluenzae, Haemophilus parahaemolyticus, S. maltophilia, 
Chryseobacterium gleum, and Enterobacter cloacae. 
A low level of discrepancy was obtained between 
MALDI-TOF MS and routine biochemical pheno-
typic tests for Haemophilus, Achromobacter, and 
Ralstonia species, as no reliable distinction at the spe-
cies level was observed. Two isolates that were mis-
identif ied by routine biochemical phenotypic tests as 
H. parainfluenzae and Haemophilus species were identified by 
MALDI-TOF MS as H. parahaemolyticus and by 16S rRNA 
sequencing analysis as Haemophilus paraphrohaemolyticus 
(Table 1). Two Achromobacter species were identified as 
A. xylosoxidans by MALDI-TOF MS, which was later 
confirmed by 16S rRNA sequencing. One NFGN organism 
was identified by phenotypic method as Ralstonia pickettii 
but was identified by MALDI-TOF MS as Achromobacter 
xylosoxidans and by 16S rRNA sequencing as A. insolitus.
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Figure 1 Identification of bacterial species by conventional phenotypic and MALDI-TOF MS methods.
Notes: The organisms listed are Staphylococcus aureus, Pseudomonas aeruginosa, Haemophilus influenzae, Streptococcus pyogenes, Achromobacter xylosoxidans, Moraxella 
catarrhalis, Haemophilus parainfluenzae, Enterobacter cloacae, Chryseobacterium gleum, Streptococcus pneumoniae, Stenotrophomonas maltophilia, Ralstonia pickettii, and Haemophilus 
parahaemolyticus.
Abbreviation: MALDI-TOF MS, matrix-assisted laser desorption/ionization-time of flight mass spectrometry.
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Table 1 Discrepancy in the identification of bacterial isolates by different methods
Phenotypic identification  
(strain number)
MALDI-TOF MS  
identification
16S rRNA gene sequence GenBank  
accession number
Haemophilus parainfluenzae (1612506366) Haemophilus parahaemolyticus Haemophilus paraphrohaemolyticus KJ128299
Haemophilus species (1612505787) Haemophilus parahaemolyticus Haemophilus paraphrohaemolyticus KJ128300
Achromobacter species I (1612508591) Achromobacter xylosoxidans Achromobacter xylosoxidans KJ128296
Achromobacter species II (1612509043) Achromobacter xylosoxidans Achromobacter xylosoxidans KJ128298
Ralstonia pickettii (1612507054) Achromobacter xylosoxidans Achromobacter insolitus KJ128297
Abbreviations: MALDI-TOF MS, matrix-assisted laser desorption/ionization-time of flight mass spectrometry; rRNA, ribosomal RNA.
Discussion
Many clinical laboratories have recently and enthusiastically 
adopted MALDI-TOF MS as a diagnostic method because 
of its high throughput, relatively low cost, and adaptability 
to the laboratory workflow; in addition, it was approved 
by the US Food and Drug Administration in the USA in 
November 2013 for the identification of Gram-negative 
bacterial colonies cultured from human specimens. The use 
of MALDI-TOF MS technique has the advantage of rapid 
microbial identification and has contributed to decreases in 
health care expenditures.14
Compared to conventional phenotypic identification 
methods, by using the database for MALDI-TOF MS-based 
identification of common pathogens from patients with 
CF, we were able to show accurate results. Identification to 
the species level typically requires numerous consecutive 
steps based on defined phenotypic assays and conventional 
approaches, which require 24–36 hours after isolation for 
obtaining definitive results. One hundred percent of our tested 
common CF isolates, which included S. aureus, P. aeruginosa, 
H. influenzae, S. pyogenes, Streptococcus pneumoniae, H. 
parainfluenzae, A. xylosoxidans, S. maltophilia, C. gleum, and 
E. cloacae, matched to the species level. This is consistent 
with other reports showing improvement in cost and time 
when using MALDI-TOF MS-based methods for common 
routine bacterial identification.15
In the present study, S. aureus was the most common 
Gram-positive organism isolated from patients with CF, 
which is in agreement with previous studies that demon-
strated the utility of MALDI-TOF MS for the identification 
of specific groups of Gram-positive bacteria, including S. 
aureus, coagulase-negative staphylococci, Streptococcus 
agalactiae, and viridans group streptococci.15,16
Correct identification of Haemophilus species based 
on phenotypic characterization can be challenging and 
standard phenotypic methods do not reliably distinguish 
among Haemophilus species.17,18 With the MALDI-TOF 
MS technology, the rarely encountered species of Hae-
mophilus can be identified.18 However, identification of 
some strains will be problematic, necessitating DNA 
sequencing of multiple housekeeping gene fragments or 
full-length 16S rRNA genes. It has been reported that the 
discrimination of closely related species H. influenzae, 
H. parainfluenzae, and Haemophilus haemolyticus is of 
diagnostic importance because of their striking differences 
in pathogenicity.17
Although highly sophisticated molecular procedures 
have been described for a reliable discrimination between 
H. haemolyticus and H. influenzae,19,20 they are hardly suitable 
for use under routine diagnostic conditions. In the present 
study, we demonstrated 100% correct identifications of H. 
influenzae and H. parainfluenzae by MALDI-TOF MS. Two 
isolates were identified as H. parahaemolyticus by MALDI-
TOF MS and as H. paraphrohaemolyticus by 16S rRNA 
gene sequencing. Although H. paraphrohaemolyticus has 
been isolated from a variety of clinical specimens,21 it has 
not been previously reported in patients with CF. In a previ-
ous study, MALDI-TOF MS analysis led to 100% correct 
identifications of H. influenzae and H. parahaemolyticus, 
but the technique failed to separate H. parainfluenzae and 
H. haemolyticus.22
Correct identification of these bacteria by conventional 
microbiology methods is often limited due to low biochemi-
cal reactivity.8
In our study, P. aeruginosa and S. maltophilia were 
correctly identified (100%) by both routine conventional 
methods and MALDI-TOF MS. However, performance of 
the MALDI-TOF MS system was more reliable for identi-
fication than conventional routine biochemical phenotypic 
tests in the case of other Gram-negative bacteria. Overall, 
five isolates of Achromobacter were correctly identified by 
MALDI-TOF MS to species level as A. xylosoxidans. Two 
discrepancies (Achromobacter species) of routine phenotypic 
and MALDI-TOF MS identifications were resolved by 16S 
rRNA gene sequencing in favor of the last one. Discrepancy 
in Achromobacter has also been reported in a recent study 
for identification of uncommon glucose NFGNB associated 
with CF.23
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Our analyses showed that isolates of species such as 
C. gleum, which is rarely reported in patients with CF, can 
be identified by both conventional and MALDI-TOF MS 
methods.24 This organism has been reported to be a source of 
nosocomial infections, capable of producing Ambler class B 
carbapenem-hydrolyzing β-lactamase,25 which might cause 
treatment failure when β-lactam antibiotics are used as a first-
line treatment. It had been thought that a limited spectrum 
of respiratory pathogens was seen in CF,26 but increasing 
numbers of other species are being recognized as potential 
pathogens. The isolation of E. cloacae from a patient with 
CF in this study may extend the potentially pathogenic list 
of organisms isolated from this group of patients.
The advantage of the MALDI-TOF MS technique is 
in providing rapid and early identification of both com-
mon and NFGNB strains recovered from patients with CF, 
apart from being a potential cost-saving method with high 
reliability.14,27 In addition, it is useful for detecting microor-
ganisms that are difficult to identify using routine biochemical 
methods. However, the performance of MALDI-TOF MS was 
not perfect for rare microorganisms due to the low number of 
isolates obtained. The system cannot determine the antimicro-
bial resistance patterns. Our results revealed important infor-
mation on the performance of MALDI-TOF MS in the rapid 
diagnosis of both common and uncommon bacteria isolated 
from the lower respiratory secretions of patients with CF.
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